Lanadelumab-Flyo
Brand name: Takhzyro
Rank #191 of 500 drugs by total cost
$76.5M
Total Cost
1,670
Total Claims
$76.5M
Total Cost
82
Prescribers
$46K
Cost per Claim
25
Beneficiaries
1,688
30-Day Fills
$933K
Avg Cost/Provider
20
Avg Claims/Provider
About Lanadelumab-Flyo
Lanadelumab-Flyo (sold as Takhzyro) was prescribed 1,670 times by 82 Medicare Part D providers in 2023, costing the program $76.5M. At $46K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 188 | Celecoxib (Celecoxib) | $77.7M | 1,938,505 |
| 189 | Sod Phenylbutyrat/Taurursodiol (Relyvrio) | $77.0M | 6,152 |
| 190 | Pravastatin Sodium (Pravastatin Sodium) | $76.8M | 4,033,829 |
| 191 | Lanadelumab-Flyo (Takhzyro) | $76.5M | 1,670 |
| 192 | Diltiazem Hcl (Diltiazem 24hr Er (Cd)) | $75.9M | 1,846,124 |
| 193 | Carvedilol (Carvedilol) | $75.6M | 6,390,691 |
| 194 | Cannabidiol (Cbd) (Epidiolex) | $75.5M | 15,726 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology